[German mRNA Startup SRTD Raises €31.5 Million Seed Fund] According to Jinse Finance, on November 9th, SRTD Biotech, a German mRNA therapy startup based in Jülich, raised €31.5 million in a seed round, which was oversubscribed. The round was led by Mérieux Equity Partners through its Mérieux Innovation 2 fund, with NRW.BANK and Boehringer Ingelheim Venture Capital participating, along with Lilly Ventures, HTGF (German High Technology Venture Fund), and Anobis Asset. Founded in 2019 by Bernd Hoffmann and Heribert Bohlen, the company's technology uses intracellular RNA disease markers to trigger mRNA expression, ensuring the therapeutic payload is generated only within diseased cells, reducing its impact on healthy tissues. This technology is called seRNA. The platform consists of seRNA technology, a fusion-type lipid nanoparticle (LNP) delivery platform capable of reaching the liver, lungs, and brain, and a synthetic biology platform combining bioinformatics and AI-driven RNA design. Alongside the financing round, the company restructured its management team: Matthias Alder became CEO, Heinz Koeppl, founder of the synthetic biology platform and professor at Darmstadt University of Technology, became CTO, and Jens Hennecke became CBO.